India

Novartis India’s board approved the transaction before the company signed an asset purchase agreement and trademark assignment deeds with Pfizer and Pfizer Products.

Ahead of the Union World Conference on Lung Health 2026, the End TB Dialogues session featured Dr MP Nezeeda, State TB Officer of Lakshadweep, who shared insights into the territory’s progress towards TB elimination.

The company said India’s Central Drugs Standard Control Organisation (CDSCO) approved the intravenous (IV) formulation, while Taiwan’s Food and Drug Administration (TFDA) approved both Hunterase IV and Hunterase ICV.

Rather than creating entirely new programmes, HPPI has worked to strengthen TB services within established HIV platforms while using a person-centred, community-led approach.

Through its dedicated pavilion, BIRAC is connecting visitors, investors and industry leaders with emerging Indian innovators while highlighting how its funding, infrastructure and mentorship programmes help turn scientific research into market-ready products.

Under the four-year agreement, Novartis India had granted Dr Reddy’s an exclusive and non-transferable right to promote, distribute and sell certain products in the Indian market.

SMT’s adoption of Teamcenter is intended to improve visibility into product development activities while helping the company manage the documentation and controls required in the highly regulated medical device industry.

The acquisition follows Novartis AG’s decision in 2024 to review the future of its India-listed subsidiary.

The consignment will replenish Kenya’s National Public Health Emergency Strategic Stockpile and support efforts to protect frontline healthcare workers during potential disease outbreaks.